Society for the Coordination of Therapeutic Researches, 20220 Algajola, France.
J Trace Elem Med Biol. 2018 Dec;50:498-507. doi: 10.1016/j.jtemb.2018.02.024. Epub 2018 Mar 8.
Many experimental models demonstrated that inorganic and organic selenium (Se) compounds may have an anticancer activity. However, large clinical studies failed to demonstrate that Se supplementations may prevent the outcome of cancers. Moreover, there are few randomized trials in cancer patients and there is not yet any Se compound recognized as anticancer drug. There is still a need to develop new Se compounds with new strategies. For that, it may be necessary to consider that Se compounds may have a dual role, either as anti-oxidant or as pro-oxidant. Experimental studies demonstrated that it is as pro-oxidant that Se compounds have anticancer effects, even though cancer cells have a pro-oxidant status. The oxidative status differs according to the type of cancer, the stage of the disease and to other parameters. We propose to adapt the doses of the Se compounds to markers of the oxidative stress, but also to markers of angiogenesis, which is strongly related with the oxidative status. A dual role of Se on angiogenesis has also been noted, either as pro-angiogenesis or as anti-angiogenesis. The objective for the development of new Se compounds, having a great selectivity on cancer cells, could be to try to normalize these oxidative and angiogenic markers in cancer patients, with an individual adaptation of doses.
许多实验模型表明，无机和有机硒（Se）化合物可能具有抗癌活性。然而，大型临床研究未能表明硒补充剂可能预防癌症的结果。此外，癌症患者的随机试验很少，也没有任何硒化合物被认为是抗癌药物。仍然需要开发具有新策略的新硒化合物。为此，可能有必要考虑硒化合物可能具有双重作用，既可以作为抗氧化剂，也可以作为促氧化剂。实验研究表明，正是作为促氧化剂，硒化合物才具有抗癌作用，尽管癌细胞具有促氧化剂状态。氧化状态根据癌症的类型、疾病的阶段和其他参数而有所不同。我们建议根据氧化应激标志物以及与氧化状态密切相关的血管生成标志物来调整硒化合物的剂量。硒对血管生成也具有双重作用，既可以促进血管生成，也可以抑制血管生成。开发对癌细胞具有高选择性的新硒化合物的目标可能是尝试在癌症患者中使这些氧化和血管生成标志物正常化，同时进行个体化剂量调整。
